Close X
Attorney Spotlight

How did an interest in healthcare policy lead Robert Platt to a career in the law? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more


Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

Shannon Wiley Outlines CMS Medicaid Drug Rebate Program Final Rule

AHLA Life Sciences and Regulation, Accreditation, & Payment Practice Groups Alert

Publications

February 3, 2016

Bass, Berry & Sims attorney Shannon Wiley outlined the details of the Centers for Medicare & Medicaid Services (CMS) final rule on the Medicaid drug rebate program that goes into effect April 1, 2016. The article focuses on the new rule related to the determination of average manufacturer price (AMP). As stated in the article, "[o]n the issue of AMP calculation, the Final Rule addressed the use of the industry norm 'presumed inclusion' approach versus the proposed 'buildup' approach when calculating sales to wholesalers for drugs distributed to retail community pharmacies."

The full article, "CMS Releases Final AMP Rule," was published by the Life Sciences and Regulation, Accreditation, & Payment Practice Groups of the American Health Lawyers Association (AHLA) on February 1, 2016. The full article is available to members to the AHLA website.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.